Pfizer Inc. is a global leader in biopharmaceuticals, offering a wide range of medicines and vaccines. The company focuses on various therapeutic areas including cardiovascular, infectious diseases, women’s health, chronic immune and inflammatory diseases, and more. Pfizer is known for its significant contributions to COVID-19 prevention and treatment with products like Comirnaty and Paxlovid. It also has a strong portfolio in biosimilars and innovative treatments across other serious health conditions. Founded in 1849 and based in New York, Pfizer collaborates with several other healthcare giants to improve global health.
Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.
Pfizer just marked a fresh 52-week high at $29.02, 1.58% above the peak it set on Aug. 25. Anyone anchored to the low-$23 range from a year ago is now looking at a very different reference point.
Seven names printed fresh 52-week highs this week, spanning travel, software and defensives. Box led with a 3.98% clearance over its prior peak, with Coca-Cola, Pfizer, Airbnb and Expedia also at new records.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
Pfizer closed at $28.24, a new 52-week high that clears the April 1 peak. The drugmaker has now taken out the ceiling that capped it all spring, making that old level the line to defend.
Investors are only learning now, 521 days late, that a Ways and Means Republican's household cleared out four positions on the same March 2025 day, including two healthcare names her committee legislates on. The filing lag is the story: disclosure rules give 45 days, and this one took more than a year past that.
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
The 5-year U.S. Treasury yield stands at 5.04%. Arguably, U.S. sovereign debt is the safest investment in the world. A bit of doubt has crept in as U.S. debt topped $40 trillion.…
A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check. Six well-known names are flashing the exact warning…
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most…
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64…
AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries…
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the…
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about…
The yield you chase to replace a six-figure salary determines far more than how much capital you need. It quietly sets your exposure to leverage, dividend cuts, and an NAV that can…
Where you hold a high-yield dividend stock matters almost as much as which one you pick, and for ordinary-income payers like BDCs and REITs, the wrong account quietly erodes a portion of…
Roth IRAs let dividends compound tax-free forever, which makes them the ideal wrapper for names that spit out ordinary-income distributions taxed at your marginal rate outside the account. The four below yield…
Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error. Here is what actually has…
Chris Lange Holding high-yield dividend stocks like BDCs and REITs in the wrong account silently erases hundreds of dollars every year, and most investors never see it happening until they run the actual numbers.
Treasury yields are making income investors work harder than they have in years, and most dividend stocks no longer clear the bar. Six still do, but yield alone is the easy part…
Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.
